NCT06925555View on ClinicalTrials.gov

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions
EBV-Positive Diffuse Large B-Cell Lymphoma, NosBrentuximab Vedotin
Interventions
DRUG

BV+R-CHP

Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5

Trial Locations (1)

210000

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06925555 - Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | Biotech Hunter | Biotech Hunter